Antibody-based immunotherapy targeting FAM19A5 reverses synaptic loss and improves cognitive function in Alzheimer's disease.
Seong, J. Y.; Kim, H.-B.; Yoo, S.; Kwak, H.; Ma, S.-X.; Kim, R.; Lee, M.; Ha, N.; Pyo, S.; Kwon, S.-G.; Cho, E.-H.; Lee, S.-M.; Jang, J.; Kim, W.; Park, H.-C.; Baek, M.; Park, Y.; Park, J.-Y.; Park, J.-W.; Hwang, S. W.; Hwang, J.-I.
Show abstract
IntroductionAlzheimers disease (AD) is characterized by the dysregulation of synaptic balance, with progressive loss of synapses outpacing formation, ultimately leading to cognitive decline. However, the lack of effective strategies for restoring lost synapses poses a major barrier to improving clinical outcomes. MethodsWe developed NS101, a monoclonal antibody targeting FAM19A5, a brain-secreted protein. Its preclinical efficacy in restoring synapses and cognition was evaluated using APP/PS1 and P301S mice. The clinical safety and target engagement of NS101 were examined in human participants. ResultsFAM19A5 binds to LRRC4B, a postsynaptic adhesion molecule, leading to synapse reduction. Blocking this interaction with NS101 normalized the rate of synapse elimination in AD mice. This synaptic rebalancing restored the number and function of synapses, resulting in improved cognition. Systemically administered NS101 facilitated the transport of brain FAM19A5 into the bloodstream. DiscussionTargeting FAM19A5 may hold clinical promise for treating AD by restoring synaptic balance.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Tau assemblies enter the cytosol in a cholesterol sensitive process essential to seeded aggregation 96%
- CTNND2 regulation by the SRGAP2 protein family links human evolution to synaptic neoteny 96%
- Drug-induced eRF1 degradation promotes readthrough and reveals a new branch of ribosome quality control 96%
Similar papers in this journal
Similar papers in this journal
- Neurons burdened by DNA double strand breaks incite microglia activation through antiviral-like signaling in neurodegeneration. 96%
- Astrocytic TDP-43 dysregulation impairs memory by modulating antiviral pathways and interferon-inducible chemokines 95%
- Mitochondrial pyruvate transport regulates presynaptic metabolism and neurotransmission 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.